All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao <scp>PDR</scp>
In this programmatic setting, the all-oral, bedaquiline and linezolid-based regimen demonstrated high effectiveness and acceptable safety. Non-significant trends favoured the all-oral regimen for treatment success, mortality, and quality of life, consistent with but not definitive for improved outcomes. These findings support the transition to all-oral regimens as the preferred approach for drug-resistant tuberculosis care, while acknowledging the observational design and limited power.
Authors
- Jacques Sébert
- Donekham Inthavong
- Philipp du Cros (ORCID: https://orcid.org/0000-0002-3599-029X)
- Sakhone Suthepmany
- Fatimata Bintou Sall (ORCID: https://orcid.org/0000-0001-9767-6952)
- Corinne Merle (ORCID: https://orcid.org/0000-0003-4229-365X)
- Vibol Iem (ORCID: https://orcid.org/0000-0001-6155-1402)
- Kyung Hyun Oh (ORCID: https://orcid.org/0000-0002-7273-3057)
- Anousone Sisouvanh
- Vongkham Inthavong
- Khamloun Choumlivong
Institutions
- National Tuberculosis Institute (IN)
- Burnet Institute (AU)
- Liverpool School of Tropical Medicine (GB)
- Rural Development Agency (LA)
- World Health Organization (CH)
- World Health Organization Regional Office for the Western Pacific (PH)
Publication Details
- Journal
- Tropical Medicine & International Health
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1111/tmi.70041
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- World Health Organization